Peripheral artery disease and risk of kidney outcomes: The Atherosclerosis Risk in Communities (ARIC) study.

Ankle-brachial index Atherosclerosis Chronic kidney disease End-stage kidney disease Peripheral artery disease

Journal

Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543

Informations de publication

Date de publication:
08 Aug 2024
Historique:
received: 17 04 2024
revised: 24 06 2024
accepted: 06 08 2024
medline: 15 9 2024
pubmed: 15 9 2024
entrez: 14 9 2024
Statut: aheadofprint

Résumé

The potential impact of peripheral artery disease (PAD) on kidney outcomes is not well understood. The aim of this study was to explore the association between PAD and end-stage kidney disease (ESKD) and chronic kidney disease (CKD). Among 14,051 participants (mean age 54 [SD 6 years]) from the Atherosclerosis Risk in Communities study, we categorized PAD status as symptomatic PAD (intermittent claudication or leg revascularization), asymptomatic PAD (ankle-brachial index [ABI] ≤0.90 without clinical history of symptoms), and ABI 0.91-1.00, 1.01-1.10, 1.11-1.20 (reference), 1.21-1.30, and >1.30. We evaluated their associations with two kidney outcomes: ESKD (the need of renal replacement therapy or death due to kidney disease) and CKD (ESKD cases or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m Over ∼30 years of follow-up, there were 598 cases of incident ESKD and 4686 cases of incident CKD. After adjusting for potential confounders, both symptomatic PAD and asymptomatic PAD conferred a significantly elevated risk of ESKD (hazard ratio 2.28 [95 % confidence interval 1.23-4.22] and 1.75 [1.19-2.57], respectively). Corresponding estimates for CKD were 1.54 (1.14-2.09) and 1.63 (1.38-1.93). Borderline low ABI 0.91-1.00 also showed elevated risk of adverse kidney outcomes after adjustment for demographic variables. Largely consistent results were observed across demographic and clinical subgroups. Symptomatic PAD and asymptomatic PAD were independently associated with an elevated risk of ESKD and CKD. These results highlight the importance of monitoring kidney function in persons with PAD, even when symptoms are absent.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
The potential impact of peripheral artery disease (PAD) on kidney outcomes is not well understood. The aim of this study was to explore the association between PAD and end-stage kidney disease (ESKD) and chronic kidney disease (CKD).
METHODS METHODS
Among 14,051 participants (mean age 54 [SD 6 years]) from the Atherosclerosis Risk in Communities study, we categorized PAD status as symptomatic PAD (intermittent claudication or leg revascularization), asymptomatic PAD (ankle-brachial index [ABI] ≤0.90 without clinical history of symptoms), and ABI 0.91-1.00, 1.01-1.10, 1.11-1.20 (reference), 1.21-1.30, and >1.30. We evaluated their associations with two kidney outcomes: ESKD (the need of renal replacement therapy or death due to kidney disease) and CKD (ESKD cases or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m
RESULTS RESULTS
Over ∼30 years of follow-up, there were 598 cases of incident ESKD and 4686 cases of incident CKD. After adjusting for potential confounders, both symptomatic PAD and asymptomatic PAD conferred a significantly elevated risk of ESKD (hazard ratio 2.28 [95 % confidence interval 1.23-4.22] and 1.75 [1.19-2.57], respectively). Corresponding estimates for CKD were 1.54 (1.14-2.09) and 1.63 (1.38-1.93). Borderline low ABI 0.91-1.00 also showed elevated risk of adverse kidney outcomes after adjustment for demographic variables. Largely consistent results were observed across demographic and clinical subgroups.
CONCLUSIONS CONCLUSIONS
Symptomatic PAD and asymptomatic PAD were independently associated with an elevated risk of ESKD and CKD. These results highlight the importance of monitoring kidney function in persons with PAD, even when symptoms are absent.

Identifiants

pubmed: 39276420
pii: S0021-9150(24)01130-4
doi: 10.1016/j.atherosclerosis.2024.118558
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118558

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: K.M. reports personal fees from Fukuda Denshi and Kowa Company, Ltd. Outside of the submitted work. The other authors do not have relevant conflicts of interest.

Auteurs

Amy Paskiewicz (A)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Frances M Wang (FM)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Junichi Ishigami (J)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Yuanjie Pang (Y)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Yingying Sang (Y)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Shoshana H Ballew (SH)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Optimal Aging Institute, Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.

Morgan E Grams (ME)

Division of Precision Medicine, Department of Medicine, New York University, New York, NY, USA.

Gerardo Heiss (G)

University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.

Josef Coresh (J)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Optimal Aging Institute, Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.

Kunihiro Matsushita (K)

Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: kuni.matsushita@jhu.edu.

Classifications MeSH